Ovarian Cancer
Conditions
Keywords
ovarian cancer, relapsed or refractory,chiauranib
Brief summary
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg，QD，PO) works in treating patients with relapsed or refractory ovarian cancer, in the meantime, exploring the latent biomarkers accompany with chiauranib, as well as the relevancy of which and clinical benefit.
Detailed description
The purpose of this study is to assess the efficacy and safety include adverse events, vital signs, laboratory tests ,etc., of Chiauranib in ovarian cancer patients due to the outcomes of the phase I study, and to explore the relevance between the latent biomarkers of Chiauranib and clinical benefit.
Interventions
DRUGChiauranib
Take 50mg orally once daily
Sponsors
Chipscreen Biosciences, Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female, aged ≥ 18 yrs and ≤70 yrs; 2. Histological or cytological confirmation of epithelial ovarian cancer, carcinoma tubae, or primary peritoneal carcinoma. 3. Patients have received platinum containing chemotherapy, a) platinum resistant disease (disease progression within 6 months of the last receipt of platinum-based chemotherapy), the disease has progressed or relapsed after at least 2 different chemotherapy regimens; b) platinum sensitive disease (disease progression after 6 months of the last receipt of platinum-based chemotherapy), the disease has progressed or relapsed at least 2 different chemotherapy regimens, or the patients refuse any chemotherapy. 4. At least 1 lesion can be accurately measured, as defined by RECIST1.1. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 6. Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, immunotherapy and surgical therapy, et al) should beyond 4 weeks prior to study entry; Subjects received mitomycin chemotherapy should beyond 6 weeks prior to study entry. 7. Laboratory criteria are as follows: Complete blood count: hemoglobin (Hb) ≥90g/L ; absolute neutrophil count (ANC) ≥1.5×109/L ; platelets \>=90×109/L Biochemistry test: total bilirubin≦1.5×ULN; alanine aminotransferase(ALT) ,aspartate aminotransferase(AST)≦1.5×ULN; (ALT,AST≦5×ULN if liver involved) ;serum creatinine(cr)≦1.5×ULN; Coagulation test: International Normalized Ratio (INR) \< 1.5. 8. Life expectancy of at least 12 weeks. 9. Willingness to sign a written informed consent document.
Exclusion criteria
1. Patients with prior invasive malignancies with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, unless received curative treatment and with documented evidence of no recurrence in the past five years; 2. Clinical evidence of central nervous system involvement; 3. Have uncontrolled or significant cardiovascular disease, including: 1. Congestive heart failure, unstable angina pectoris, myocardial infarction within 6 months prior to study entry; arrhythmia, or Left Ventricular Ejection Fraction (LVEF) \< 50% requiring treatment with agents during screening stage. 2. primary cardiomyopathy(dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al) 3. History of significant QT interval prolongation, or Corrected QT Interval (QTc) \> 470 ms prior to study entry 4. Symptomatic coronary heart disease requiring treatment with agents 5. Uncontrolled hypertension (\> 140/90 mmHg) by single agent. 4. Have active bleeding current thrombotic disease, patients with bleeding potential ,or receiving anticoagulation therapy; within 2 months prior to screening; 5. Proteinuria positive(≥1g/24h). 6. History of deep vein thrombosis or pulmonary embolism; 7. Have unsolved toxicities (\> grade 1) from prior anti-cancer therapy; 8. Have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption of oral agents, or patients undergone gastrectomy. 9. History of organ transplantation. 10. Major surgery within 6 weeks and minor surgery within 2 weeks prior to screening (excluding placement of vascular access or biopsy) that involved general anaesthesia or respiratory assistance. 11. Serologically positive for HIV, hepatitis B or C, or other serious infectious diseases. 12. History of interstitial lung disease(ILD). 13. Previous treatment with aurora kinase inhibitors. 14. Any mental or cognitive disorder, that would impair the ability to understand the informed consent document or the operation and compliance of study; 15. Candidate with drug and alcohol abuse. 16. Participants of reproductive potential not willing to use adequate contraceptive measures for the duration of the study (both male and female participants).Pregnant or breastfeeding women. Female participants must have a negative urinary or serum pregnancy test when done or have evidence of post-menopausal status (Defined as absence of menstruation for greater than 12 months, bilateral oophorectomy or hysterectomy). 17. Any other condition which is inappropriate for the study in the opinion of the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate(ORR) | assessed up to 2 years | ORR will be calculated from the data obtained from the end visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to progression(TTP) | through treatment completion, up to 2 years | duration from date of treatment until the date of first documented progression |
| Duration of response (DOR) | assessed up to 2 years | From the first date of response until the date of first documented progression |
| Overall survival(OS) | assessed up to 2 years | Time from treatment to death from any cause |
| 16 week-disease control rate(16W-DCR) | assessed up to 2 years | Rate of the patients with disease control longer than 6 weeks |
| Number of participants with treatment-related adverse events | measured through 2 years | measured by adverse events (AE), serious adverse events (SAE), abnormal vital signs，electrocardiograph(ECG) and abnormal laboratory results according to CTCAE V4.03 |
| Progression-free survival (PFS) | assessed up to 2 years | From date of treatment until the date of first documented progression or date of death from any cause, whichever came first |
Other
| Measure | Time frame | Description |
|---|---|---|
| Mutation of polygene and copy number variation in signal pathway(multi-gene analysis) | assessed up to 2 years | — |
| immunohistochemical(IHC) staining results of Aurora B、CSF-1R and Myc protein | assessed up to 2 years | The IHC staining results were assigned a mean follows: 0, negative; 1, weak; 2, moderate; and 3, strong. The frequency of positive cells was defined as follows: 0, less than 5%; 1, 5% to 25%; 2, 26% to 50%; 3, 51% to 75%; and 4,greater than 75%. |
| Any single mutation of oncogene and copy number variation in ctDNA(single gene analysis) | assessed up to 2 years | — |
Countries
China
Outcome results
None listed